AI Proteins
Bobby W Sandage, Jr., PhD, is an accomplished professional with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Interim Head of Development and Board Member at AI Proteins since July 2022, Sandage also holds board positions at Microbial Machines, NextRNA Therapeutics, Geneoscopy, and BioVentures, LLC. As Managing Director of the Paula and Rodger Riney Foundation, Sandage is dedicated to finding a cure for multiple myeloma. In addition, as General Partner at Cultivation Capital Life Sciences Fund II since September 2016, Sandage focuses on advancing early-stage life sciences companies. Sandage's leadership as President and CEO of Euclises Pharmaceuticals, Inc. emphasizes the development of novel oral treatments for COX-2/PGE-2 driven cancers. Educational credentials include a Ph.D. in Clinical Pharmacy from Purdue University and a BS in Pharmacy from the University of Arkansas for Medical Sciences.
This person is not in any teams
This person is not in any offices
AI Proteins
AI Proteins is a biotechnology company that focuses on designing and engineering of synthetic miniprotein therapeutics.